Literature DB >> 26617755

Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway.

Qingtang Miao1, Sibin Hao1, Hongmei Li1, Fang Sun1, Xueling Wang1.   

Abstract

Femoral head avascular necrosis (AVN) causes the damage of hip joint and related dysfunctions, thus consisting of a clinical challenge. Osteoprotegerin (OPG), receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) all regulate the formation of bones via gene transcriptional regulation for the balance between osteoblasts and osteoclasts. This study thus investigated the expressional profiles of OPG, RANK and RANKL genes in AVN patients, and explored related molecular mediating pathways. Real-time qPCR was used to measure the gene expression of OPG, RANK and RANKL genes in AVN femoral head tissue samples from 42 patients, along with normal tissues. Western blotting analysis was performed to quantify protein levels of OPG and RANKL. There was a trend but not statistically significant elevation of mRNA levels of OPG in femoral head AVN tissues compared to normal tissues (P>0.05). The expression of RNAK and RNAKL, however, was significantly elevated in necrotic tissues (P<0.05). No significant difference in protein levels of OPG or RANKL between groups. The expression of OPG, RANK and RANKL genes exert a crucial role in the progression of AVN, suggesting their roles in mediating bone homeostasis and potential effects on bone destruction.

Entities:  

Keywords:  Femoral head avascular necrosis; gene expression regulation; ligand for receptor activator of nuclear factor κB; osteoprotegerin; receptor activator of nuclear factor κB

Mesh:

Substances:

Year:  2015        PMID: 26617755      PMCID: PMC4637570     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  28 in total

1.  The 677C-->T mutation of the methylene-tetrahydrofolate reductase gene in the pathogenesis of osteonecrosis of the femoral head.

Authors:  Charalampos G Zalavras; Konstantinos N Malizos; Eleni Dokou; George Vartholomatos
Journal:  Haematologica       Date:  2002-01       Impact factor: 9.941

2.  Treatment of avascular necrosis of the femoral head with vascularized fibular transplant.

Authors:  P N Soucacos; A E Beris; K Malizos; A Koropilias; H Zalavras; Z Dailiana
Journal:  Clin Orthop Relat Res       Date:  2001-05       Impact factor: 4.176

3.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

Authors:  W S Browner; L Y Lui; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.

Authors:  A E Hughes; S H Ralston; J Marken; C Bell; H MacPherson; R G Wallace; W van Hul; M P Whyte; K Nakatsuka; L Hovy; D M Anderson
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

Review 5.  Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.

Authors:  J E Aubin; E Bonnelye
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

6.  High quality RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays: application to chondrosarcoma.

Authors:  H J Baelde; A M Cleton-Jansen; H van Beerendonk; M Namba; J V Bovée; P C Hogendoorn
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

7.  Hypofibrinolysis, thrombophilia, osteonecrosis.

Authors:  C J Glueck; R A Freiberg; R N Fontaine; T Tracy; P Wang
Journal:  Clin Orthop Relat Res       Date:  2001-05       Impact factor: 4.176

Review 8.  Bone morphogenetic proteins in vascular calcification.

Authors:  Keith A Hruska; Suresh Mathew; Georges Saab
Journal:  Circ Res       Date:  2005-07-22       Impact factor: 17.367

Review 9.  RANK/RANKL: regulators of immune responses and bone physiology.

Authors:  Andreas Leibbrandt; Josef M Penninger
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 10.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

View more
  3 in total

Review 1.  Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: a therapeutic challenge.

Authors:  Michaela Kuhlen; Marina Kunstreich; Kathinka Krull; Roland Meisel; Arndt Borkhardt
Journal:  Blood Adv       Date:  2017-06-13

2.  Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients.

Authors:  Giuliano Vezzani; Silvia Quartesan; Pasqua Cancellara; Enrico Camporesi; Devanand Mangar; Thomas Bernasek; Prachiti Dalvi; Zhongjin Yang; Antonio Paoli; Alex Rizzato; Gerardo Bosco
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

3.  Comprehensive analysis of pivotal biomarkers, immune cell infiltration and therapeutic drugs for steroid-induced osteonecrosis of the femoral head.

Authors:  Bo Wang; Song Gong; Wenkai Shao; Lizhi Han; Zilin Li; Zhichao Zhang; Yang Zheng; Fang Ouyang; Yan Ma; Weihua Xu; Yong Feng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.